This clinical trial is focused on studying the effects of a medication called aticaprant on individuals with Major Depressive Disorder (MDD). The study aims to evaluate if adding aticaprant to a current antidepressant treatment is safe and can help improve symptoms of depression. Participants in the study will continue taking their existing antidepressant, which could be a type known as an SSRI or SNRI, while also taking aticaprant.
The purpose of the study is to assess the long-term safety and tolerability of aticaprant when used alongside a current antidepressant. The study will involve taking aticaprant in the form of a tablet by mouth. Participants will be monitored over a period of up to one year to observe any changes in their condition and to ensure the treatment is safe. The study will also look at various health indicators, such as vital signs, weight, and any side effects that may occur.
Throughout the study, participants will undergo regular health checks, including physical examinations and heart tests known as ECGs, to ensure they remain in good health. The study will also assess any changes in mood or behavior, including any thoughts of self-harm, using a specific rating scale. This trial is designed to provide valuable information on whether aticaprant can be a beneficial addition to existing depression treatments.
Belgium 
Bulgaria 
Czechia 
France 
Hungary 
Italy 
Poland 
Portugal 
Slovakia 
Spain 
Sweden 
